Systematic review on the prevention and control of blood-borne viruses in prison settings
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Hepatitis B - Annual Epidemiological Report for 2016
In 2016, 30 EU/EEA Member States reported 29 307 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 5.5 cases per 100 000 population.
Laboratory testing of non-partner sperm donors
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Surveillance systems overview for 2015
This spreadsheet contains all surveillance system overview tables from the ECDC Annual Epidemiological Reports for 2015.
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- hantavirus infection
- healthcare-associated infections
- hepatitis A
- hepatitis B
- hepatitis C
- HIV infection
- invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- meningococcal disease
- pneumococcal disease
- Q fever
- Rift Valley fever
- severe acute respiratory syndrome
- surgical site infections
- verotoxigenic Escherichia coli infection
- West Nile fever
- yellow fever
Hepatitis B - Annual Epidemiological Report for 2015
In 2015, 30 EU/EEA Member States reported 24 573 cases of hepatitis B virus (HBV) infection, a crude rate of 4.7 cases per 100 000 population.